Literature DB >> 18338238

Validation of the French version of the colorectal-specific quality-of-life questionnaires EORTC QLQ-CR38 and FACT-C.

Christine Rotonda1, T Conroy, M Mercier, F Bonnetain, L Uwer, J Miny, P Montcuquet, I Léonard, A Adenis, G Breysacher, F Guillemin.   

Abstract

BACKGROUND: The aim of this study was to test the psychometric properties of the French version of the European Organization for Research and Treatment (EORTC) quality-of-life colorectal questionnaire (QLQ-CR38) and the functional assessment of cancer therapy-colorectal version 4 (FACT-C).
METHOD: This prospective study included 209 patients with colorectal cancer: 71 undergoing chemotherapy, 56 radiation, 15 surgery, and 67 survivors. Patients first completed in random order the FACT-C and the EORTC QLQ-CR38 and were asked if they had any preference for either questionnaire. The timing of administration of instruments differed according to patients' treatment to better assess psychometric properties.
RESULTS: The FACT-C showed good acceptability, good reproducibility and excellent internal consistency. The QLQ-CR38 had lower internal consistency. Patients did not express a preference for one survey over another.
CONCLUSION: This study confirms the value of the FACT-C and suggests some limits of the QLQ-CR38 for patients with colorectal cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18338238     DOI: 10.1007/s11136-008-9322-9

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  24 in total

1.  The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Organization for Research and Treatment of Cancer Study Group on Quality of Life.

Authors:  M A Sprangers; A te Velde; N K Aaronson
Journal:  Eur J Cancer       Date:  1999-02       Impact factor: 9.162

2.  Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches.

Authors:  K J Yost; D Cella; A Chawla; E Holmgren; D T Eton; J Z Ayanian; D W West
Journal:  J Clin Epidemiol       Date:  2005-10-13       Impact factor: 6.437

3.  The impact of recurrent rectal cancer on quality of life.

Authors:  J Camilleri-Brennan; R J Steele
Journal:  Eur J Surg Oncol       Date:  2001-06       Impact factor: 4.424

4.  Quality of life in colorectal cancer patients with colectomy and the validation of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C), Version 4.

Authors:  Hee Jung Yoo; Jin Cheon Kim; Sonya Eremenco; Oh Su Han
Journal:  J Pain Symptom Manage       Date:  2005-07       Impact factor: 3.612

5.  Assessment of quality of life in patients with rectal cancer treated by preoperative radiotherapy: a longitudinal prospective study.

Authors:  Abdelkarim S Allal; Pascal Gervaz; Philippe Gertsch; Jacques Bernier; Arnaud D Roth; Philippe Morel; Sabine Bieri
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-15       Impact factor: 7.038

6.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

Authors:  D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

7.  French version of FACT-G: validation and comparison with other cancer-specific instruments.

Authors:  T Conroy; M Mercier; J Bonneterre; E Luporsi; J L Lefebvre; M Lapeyre; M Puyraveau; S Schraub
Journal:  Eur J Cancer       Date:  2004-10       Impact factor: 9.162

8.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

9.  Patient preference for either the EORTC QLQ-C30 or the FACIT Quality Of Life (QOL) measures: a study performed in patients suffering from carcinoma of an unknown primary site (CUP).

Authors:  C Rodary; V Pezet-Langevin; S Garcia-Acosta; T Lesimple; A Lortholary; M C Kaminsky; J Bennouna; S Culine; H Bourgeois; Karim Fizazi
Journal:  Eur J Cancer       Date:  2004-03       Impact factor: 9.162

Review 10.  Assessing quality of life in patients with colorectal cancer: an update of the EORTC quality of life questionnaire.

Authors:  S Gujral; T Conroy; C Fleissner; O Sezer; P M King; K N L Avery; P Sylvester; M Koller; M A G Sprangers; J M Blazeby
Journal:  Eur J Cancer       Date:  2007-05-22       Impact factor: 9.162

View more
  10 in total

1.  The internal and external responsiveness of Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Short Form-12 Health Survey version 2 (SF-12 v2) in patients with prostate cancer.

Authors:  Edmond P H Choi; Carlos K H Wong; Eric Y F Wan; James H L Tsu; W Y Chin; Kenny Kung; M K Yiu
Journal:  Qual Life Res       Date:  2016-02-23       Impact factor: 4.147

2.  Cultural adaptation and validation of the Korean version of the EORTC QLQ-CR29 in patients with colorectal cancer.

Authors:  Myong Hoon Ihn; Sung-Min Lee; Il Tae Son; Jin Taek Park; Heung-Kwon Oh; Duck-Woo Kim; Sung-Bum Kang
Journal:  Support Care Cancer       Date:  2015-04-01       Impact factor: 3.603

3.  Health-related quality of life of breast and colorectal cancer patients undergoing active chemotherapy treatment: Patient-reported outcomes.

Authors:  Isamme AlFayyad; Mohamad Al-Tannir; Jude Howaidi; Dana AlTannir; Amani Abu-Shaheen
Journal:  Qual Life Res       Date:  2022-04-30       Impact factor: 3.440

Review 4.  Comparison of the FACT-C, EORTC QLQ-CR38, and QLQ-CR29 quality of life questionnaires for patients with colorectal cancer: a literature review.

Authors:  Vithusha Ganesh; Arnav Agarwal; Marko Popovic; David Cella; Rachel McDonald; Sherlyn Vuong; Henry Lam; Leigha Rowbottom; Stephanie Chan; Tasneem Barakat; Carlo DeAngelis; Michael Borean; Edward Chow; Andrew Bottomley
Journal:  Support Care Cancer       Date:  2016-05-18       Impact factor: 3.603

5.  Quality-of-life and surgical treatments for rectal cancer--a longitudinal analysis using the California Cancer Registry.

Authors:  Julie Smith-Gagen; Rosemary D Cress; Christiana M Drake; Patrick S Romano; Kathleen J Yost; John Z Ayanian
Journal:  Psychooncology       Date:  2010-08       Impact factor: 3.894

6.  Measurement invariance of the Functional Assessment of Cancer Therapy-Colorectal quality-of-life instrument among modes of administration.

Authors:  Carlos K H Wong; Cindy L K Lam; Brendan Mulhern; Wai-Lun Law; Jensen T C Poon; Dora L W Kwong; Janice Tsang
Journal:  Qual Life Res       Date:  2012-09-28       Impact factor: 4.147

7.  Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer.

Authors:  T Conroy; M Hebbar; J Bennouna; M Ducreux; M Ychou; G Llédo; A Adenis; R Faroux; C Rebischung; L Kockler; J Y Douillard
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

8.  Validation of the Danish version of the disease specific instrument EORTC QLQ-CR38 to assess health-related quality of life in patients with colorectal cancer.

Authors:  Henriette Vind Thaysen; P Jess; Søren Laurberg; M Groenvold
Journal:  Health Qual Life Outcomes       Date:  2012-12-14       Impact factor: 3.186

Review 9.  Health related quality of life in colorectal cancer patients: state of the art.

Authors:  Stefano Marventano; Maria Forjaz; Giuseppe Grosso; Antonio Mistretta; Gabriele Giorgianni; Alessio Platania; Santi Gangi; Francesco Basile; Antonio Biondi
Journal:  BMC Surg       Date:  2013-10-08       Impact factor: 2.102

10.  Transcultural adaptation and validation of the Serbian version of the colorectal-specific quality of life questionnaire FACT-C.

Authors:  Jelena Ilic-Zivojinovic; Igor Krdzic; Ana Jovanovic; Danka Vukasinovic; Branislav Ilic; Aleksandar Gavrilovic; Ivan Soldatovic
Journal:  PLoS One       Date:  2022-02-03       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.